Revenue segments as reported by the company.

Water

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IDEXX Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IDEXX Labs reports robust Q4 performance, eyes international growth

IDEXX Laboratories delivered strong Q4 results with revenue and profit growth, driven by gains in key segments and customer retention.
While facing challenges from inflationary costs and international headwinds, the company aims for continued growth and market differentiation.
Opportunities lie in expanding organic revenue, focusing on international markets, and enhancing customer engagement for future success.

IDEXX reports robust Q1 performance, eyes pet oncology growth

IDEXX Laboratories delivered a strong Q1 performance with revenue and profit growth across segments.
The company's focus on innovation, cloud adoption, and pet oncology diagnostics positions it well for future growth.
Challenges include U.S. clinical vet visit trends and potential market share competition in lab modalities.
Opportunities lie in pet oncology diagnostics, cloud adoption, and international market growth for IDEXX.

IDEXX Laboratories excels in Q2, eyes pet healthcare trends

IDEXX Laboratories demonstrated robust growth in revenues and profitability, driven by strong performance in key segments.
While facing challenges in international markets and margin pressures, the company is poised to capitalize on pet healthcare trends.
Strategic initiatives like product launches and pricing adjustments position IDEXX well for sustained growth and market leadership.

IDEXX Laboratories excels in Q3 earnings amidst capacity challenges

IDEXX Laboratories demonstrated strong financial performance in Q3, driven by revenue growth and operational efficiency.
While facing challenges in clinical visit trends and capacity management, the company's strategic focus on innovation and market expansion positions it well for future growth.
Opportunities lie in addressing capacity constraints, expanding the sales force, and enhancing customer engagement through diagnostics testing.
Overall, IDEXX's commitment to providing integrated solutions and quality services underscores its resilience and potential for sustained success.

IDEXX Labs posts robust Q4 results, eyes growth through innovation

IDEXX Laboratories delivered strong financial performance in Q4 2023 and aims for continued growth in 2024.
The company's focus on innovation, customer feedback, and operational efficiency positions it well for future success.
Challenges include managing expenses, revenue diversification, and maintaining customer value perception.
Opportunities lie in organic revenue growth, margin improvement, and the launch of new diagnostic tests and platforms.

IDEXX Laboratories reports strong Q1 earnings and growth opportunities

IDEXX Laboratories delivered strong financial performance in Q1 2024, driven by solid organic revenue growth and profit gains.
The company remains committed to innovation, customer-centric solutions, and increasing standard of care in Companion Animal Healthcare.
Challenges in clinical visit growth levels and macro impacts on consumer demand are being addressed through operational focus and technology investments.
Opportunities for growth and improvement in software integration and diagnostic utilization dynamics present avenues for future success.

IDEXX Laboratories reports solid Q2 growth amidst sector challenges

IDEXX Laboratories navigated Q2 2024 with solid revenue growth and a focus on innovation and cost management. Despite challenges from sector trends and macroeconomic headwinds, the company remains optimistic about long-term growth prospects. Ongoing launches and a strong balance sheet position IDEXX well for future opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2023 first quarter results for Tuesday, May 2, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2023 Earnings Snapshot through a link on the IDEXX website, www.idexx.

IDEXX Laboratories to Release 2023 First Quarter Financial Results

Alcon Inc. - Registered Shares

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Idexx Laboratories (IDXX). But which of these two stocks offers value investors a better bang for their buck right now?

ALC vs. IDXX: Which Stock Is the Better Value Option?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Why Is Idexx (IDXX) Down 6.6% Since Last Earnings Report?

IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.

IDEXX (IDXX) Global Sales, Instrument Placement Robust

IDEXX Laboratories, Inc. is a U.S. healthcare company, that currently leads the veterinary industry developing diagnostics tools to satisfy veterinarians' everyday needs. IDEXX has delivered solid and consistent results that rival those of Google's, Metas', and Microsoft's out there.

IDEXX Laboratories: Excellent Business But Extremely Overpriced

Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year.

Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?

Major gains possible by optimizing workflow, applying technology smartly, and improving talent management WESTBROOK, Maine , Feb. 20, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced a first-of-its-kind empirical study aimed at addressing veterinary practice capacity constraints. In the publication Finding the Time: Empowering Veterinary Teams to Get the Most Out of Every Day, IDEXX introduces the veterinary Practice Productivity Index™, a data-driven framework and collection of guides for transforming practice productivity across the dimensions of workflow, technology, and culture.

Groundbreaking IDEXX Study Reveals Opportunities to Increase Veterinary Practice Productivity

Pinterest

Despite underwhelming earnings reports, these businesses remain great investments in 2023.

2 Top Stocks I'm Buying Hand Over Fist in February

AbbVie

Align Technology

Baxter

BeiGene

Centene

Exact Sciences

GE HealthCare Technologies Inc

Neurocrine Biosciences

Pfizer

After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022.

5 Best and Worst Performing Healthcare Stocks in January 2023

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2022 Results Conference Call February 6, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Chief Financial Officer John Ravis - Vice President, Investor Relations Conference Call Participants Nathan Rich - Goldman Sachs Chris Schott - JPMorgan Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Jon Block - Stifel Ryan Daniels - William Blair Operator Good morning, and welcome to the IDEXX Laboratories Fourth Quarter 2022 Earnings Conference Call. As a reminder, today's conference is being recorded.

IDEXX Laboratories, Inc. (IDXX) Q4 2022 Earnings Call Transcript

IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases

Idexx (IDXX) delivered earnings and revenue surprises of 6.77% and 1.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates

Achieves fourth quarter revenue growth of 3% reported and 7% organic, driven by CAG Diagnostics recurring revenue growth of 4% reported and 8% organic  Solid growth supported by continued benefits from IDEXX execution drivers, including 13% year-over-year expansion of IDEXX's global premium instrument installed base Delivers fourth quarter EPS of $2.05, an increase of 8% as reported and 14% on a comparable basis, supported by operating margin expansion Provides initial outlook for 2023 revenue of $3,590 million - $3,690 million, reflecting reported growth of 6.5% - 9.5% and organic growth of 7% - 10% Estimates 2023 EPS of $9.27 - $9.75, an increase of 16% - 21% as reported and 19% - 26% on a comparable basis, including ~ 10% growth benefit from lapping discrete R&D investments in 2022 WESTBROOK, Maine , Feb. 6, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results, as well as an update on U.S. companion animal diagnostic trends. Fourth Quarter and Full Year Results The Company reports revenues of $829 million for the fourth quarter of 2022, an increase of 3% compared to the prior year period on a reported basis and 7% on an organic basis.

IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results

Sonova Holding AG

SONVY vs. IDXX: Which Stock Is the Better Value Option?

SONVY or IDXX: Which Is the Better Value Stock Right Now?

Expedia

SolarEdge Technologies

Sanofi

Tradeweb Markets

Five Nasdaq Composite companies are set to beat earnings estimates. These are: EXPE, IDXX, SNY, TW and SEDG.

Top 5 Nasdaq Composite Stocks to Buy Ahead of Q4 Earnings

WESTBROOK, Maine , Jan. 26, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2022 fourth quarter and full year financial results for Monday, February 6, 2023 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m.

IDEXX Laboratories to Release 2022 Fourth Quarter and Full Year Financial Results

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Apple

Amazon

Alphabet

MercadoLibre

Microsoft

NVIDIA

Atlassian

Tesla

Warner Bros Discovery Inc

The Nasdaq composite is up 6.44% in 2023, its best start to a new year. These are the big Nasdaq winners, including some megacaps.

Nasdaq Off To Its Fastest Start Since 2019 — These Stocks Are Leading The Charge

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Idexx (IDXX) Could Beat Earnings Estimates Again

IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.

IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement

Airbnb

ASML Hld

SPDR Dow Jones Industrial Average ETF

Invesco QQQ

SPDR S&P 500 ETF Trust

The rally has been broad-based. And the high beta and high growth sector took charge, with the tech-heavy Nasdaq Composite Index rising 5.1% in the initial two weeks of 2023.

5 Stocks Powering Nasdaq ETF to Start 2023

Volitionrx Limited

VolitionRx Ltd (NYSE-A:VNRX) has announced the availability of its Nu.Q Vet Cancer Test through the IDEXX Laboratories Inc reference laboratory network in the US. The Henderson, Nevada-based multi-national epigenetics company noted that IDEXX is a global leader in pet healthcare innovation and is well-positioned to roll out the IDEXX Nu.Q Canine Cancer Screen worldwide.

VolitionRx announces expansion of availability of Nu.Q Vet Cancer Test availability through IDEXX's reference laboratory network

Adobe

Best Buy

Cadence Design Systems

Salesforce

Intuit

Lam Research

Pool

Support good corporate citizenship (and build wealth) with these stocks.

10 Best Stocks for Environmental, Social, and Governance (ESG) Investing

Interactive Brokers

Intel

JD.com

Monster Beverage

PepsiCo

After watching the Nasdaq lose roughly a third of its value in 2022, investors might rightly be wary of that particular stock exchange. However, the truth is that there are still plenty of Nasdaq stocks that have created tremendous wealth for long-term investors.

7 Nasdaq Stocks to Buy and Hold Forever

Boston Omaha

Chipotle

By focusing on her interests, I hope to show my daughter that fascinating businesses are all around her.

News for IDEXX Laboratories Stock (IDXX)